| Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis | 09/17 07:00 | globenewswire.com |
| Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference | 09/10 07:00 | globenewswire.com |
| Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates | 08/07 09:16 | zacks.com |
| Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year? | 07/25 10:41 | zacks.com |
| AllClear Repair Services Approved as Honeywell Authorized Service Center | 07/23 08:45 | businesswire.com |
| Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million | 07/16 16:01 | globenewswire.com |
| 3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices | 07/11 07:12 | marketbeat.com |
| Rheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte) | 06/25 12:36 | globenewswire.com |
| Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference | 06/06 07:00 | globenewswire.com |
| American Clinical Research Services Announces Strategic Acquisition of Elixia | 05/08 06:30 | businesswire.com |